Comparative Pharmacology
Head-to-head clinical analysis: PARACORT versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARACORT versus TEXACORT.
PARACORT vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paracort is a corticosteroid that acts by binding to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines and prostaglandins.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Prednisone 5-60 mg orally once daily; initial dose 5-15 mg daily; for acute conditions, up to 60 mg daily tapered over 2-3 weeks.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5–4.5 hours) in adults with normal renal function; prolonged to up to 10–15 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal elimination of unchanged drug accounts for approximately 70% of the dose; biliary/fecal excretion accounts for 20%; the remainder is metabolized and excreted as inactive metabolites.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid